Peptide Schedule
OrforglipronSmall moleculeNo amino acid sequence. Icon reflects category theme only.Orforglipron
Benefits
About Orforglipron
Orforglipron (brand name Foundayo) is the first oral non-peptide GLP-1 receptor agonist — and that distinction matters. Unlike semaglutide, tirzepatide, and every other GLP-1 drug on the market, it isn't a peptide at all. It's a small-molecule compound built on a rigid polycyclic heteroaromatic scaffold, which means it survives stomach acid and absorbs through the gut without the enteric coatings or absorption enhancers that oral semaglutide (Rybelsus) requires. You can take it any time of day, with or without food, with no water restrictions. Eli Lilly developed orforglipron (originally LY3502970/OWL-833) and received FDA approval on April 1, 2026 — just 50 days after filing the NDA, making it the fastest approval of a new molecular entity since 2002. It was the fifth drug approved under the FDA's National Priority Voucher program. In the ATTAIN-1 trial (3,127 adults with obesity but without diabetes), the highest dose produced an average weight loss of 27.3 lbs (12.4%) over 72 weeks versus 2.2 lbs (0.9%) with placebo. The ATTAIN-2 trial confirmed similar efficacy in people with type 2 diabetes. And in the head-to-head ACHIEVE-3 trial, orforglipron 36mg beat oral semaglutide 14mg for both HbA1c reduction and weight loss — though it's worth noting the ORION indirect comparison found higher-dose oral semaglutide (25mg) may edge ahead on pure weight loss. The GI side effect profile is typical for GLP-1 drugs — nausea, vomiting, diarrhea — and discontinuation rates due to GI events were higher than injectable options. But for millions of people who won't use needles, an effective oral option at $149/month self-pay changes the accessibility equation entirely.
Who Should Consider Orforglipron
- Adults with BMI ≥30 (obesity)
- Adults with BMI ≥27 plus at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA)
- People who prefer oral medication over injections
- Patients switching from injectable GLP-1s who want to maintain weight loss orally
- Type 2 diabetics seeking combined glycemic and weight control
How Orforglipron Works
Orforglipron is a non-peptide allosteric agonist of the GLP-1 receptor. Instead of binding to the orthosteric peptide-binding pocket where native GLP-1 and semaglutide attach, it binds within the transmembrane core of the receptor (TM1, TM2, TM3, TM7, and ECL2), stabilizing an active conformation that preferentially activates Gs-protein signaling. This triggers the same downstream effects as injectable GLP-1 drugs: glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from alpha cells, delayed gastric emptying, and appetite reduction via hypothalamic and brainstem GLP-1 receptors. What makes orforglipron different at the molecular level is its small-molecule scaffold. At 883 Da (molecular formula C48H48F2N10O5), it's a fraction of the size of peptide-based GLP-1 agonists and resistant to proteolytic degradation in the GI tract. Oral bioavailability sits around 79%, and it's metabolized primarily through hepatic CYP3A4. The terminal half-life ranges from 29 to 68 hours depending on dose and duration of use, supporting once-daily oral dosing without water or food restrictions.
What to Expect
Starting dose 0.8mg. Mild appetite suppression begins. GI side effects (nausea, stomach discomfort) most likely during this period. Minimal weight change expected.
Titrating through 2.5mg and 5.5mg. Appetite reduction becomes more noticeable. Early weight loss of 2-4% body weight. Nausea typically fades as each dose level stabilizes.
Reaching maintenance doses (9-17.2mg). Steady weight loss averaging 0.5-1 lb/week. Measurable improvements in waist circumference and metabolic labs.
Weight loss approaches 10-12% average at the highest dose based on ATTAIN-1 data. Triglycerides, non-HDL cholesterol, and blood pressure improve. Rate of loss slows as new equilibrium is reached.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5.5mg | Daily |
| Moderate | 14.5mg | Daily |
| Aggressive | 17.2mg | Daily |
Note: Oral tablet — no injection, no reconstitution. Brand name Foundayo. FDA-approved April 2026. Titrate from 0.8mg daily: 0.8mg x 30 days, then 2.5mg x 30 days, then 5.5mg x 30 days, then increase to 9mg, 14.5mg, or 17.2mg based on response. Take with or without food — no water or fasting restrictions.
How to Inject Orforglipron
Take one tablet by mouth once daily, with or without food, at any time of day. Swallow whole — don't break, crush, or chew. Titration: start at 0.8mg daily for 30 days, increase to 2.5mg for 30 days, then 5.5mg for 30 days, then escalate to 9mg, 14.5mg, or 17.2mg based on tolerability and response. If you miss a dose, take it as soon as you remember (don't double up). If you've missed 7+ consecutive days, restart from 0.8mg.
Cycling Protocol
Intended for continuous long-term use. Weight regain expected after stopping — same as other GLP-1 drugs. If you miss 7 or more consecutive days, restart the titration schedule.
Pharmacokinetics
Source: Pratt et al. Phase 1a (PMID 37344954); steady-state t½ 48-68h across dose range
Loading the interactive decay curve.
Side Effects
The side effect profile tracks with other GLP-1 drugs but skews a bit higher on GI complaints, probably because oral delivery means direct contact with the stomach lining. Nausea is the most common issue, followed by constipation, diarrhea, vomiting, and dyspepsia. Abdominal pain, headache, fatigue, burping, heartburn, gas, and hair loss are also reported. In clinical trials, discontinuation due to GI adverse events ran about 4x higher than with oral semaglutide — that's the main trade-off for the dosing convenience. Slow titration over 2-3 months helps a lot. More serious risks include pancreatitis, acute kidney injury (usually from dehydration during GI episodes), gallbladder disease, and a theoretical thyroid tumor risk carried over from the GLP-1 class. There's a black box warning for medullary thyroid carcinoma based on animal data.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Known hypersensitivity to orforglipron or any excipient
- Concurrent use with other GLP-1 receptor agonists
- Pregnancy or planning to become pregnant
Drug Interactions
- CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) — may increase orforglipron exposure; monitor closely
- CYP3A4 inducers (rifampin, carbamazepine, phenytoin) — may reduce orforglipron levels and efficacy
- Insulin and sulfonylureas — increased hypoglycemia risk; dose reduction of the secretagogue often needed
- Oral medications with narrow therapeutic windows — gastric emptying delay may alter absorption timing; monitor drugs like warfarin, digoxin, and levothyroxine
Storage & Stability
Related Peptides
References
- ATTAIN-1 — Orforglipron for Obesity (Phase 3)PubMed 40960239
- ATTAIN-2 — Orforglipron for Obesity with Type 2 Diabetes (Phase 3, Lancet)PubMed 41275875
- Phase 2 — Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (NEJM)PubMed 37351564
- Phase 1a — Orforglipron Single- and Multiple-Ascending-Dose StudyPubMed 37344954
- Orforglipron Comprehensive Review (IJMS 2025)Review
- FDA Approval — Foundayo Prescribing InformationFDA Label